Goodman Noah sold $387K of KYMR
Goodman Noah (Chief Business Officer) sold 3,389 shares of Kymera Therapeutics, Inc. (KYMR) at $114.29 ($0.39M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This discloses an officer’s open-market sale (3,389 shares) at a stated price, but the presence of a pre-arranged 10b5-1 plan typically lowers the signal-to-noise for near-term trading decisions.
Market read
Traders may note the sale for sentiment monitoring, but it is unlikely to change valuation absent accompanying fundamental news.
What to watch
Insider sales can be misread without context (taxes, diversification, planned compensation monetization); also, the filing date may lag the actual sale, reducing immediacy.
Background
The article is a primary-source SEC Form 4 insider transaction for Kymera Therapeutics (KYMR).
Ticker impact
Kymera Therapeutics insider Goodman Noah sold 3,389 shares on 2026-07-01 at $114.29 under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.
The filing is a disclosed open-market sale by an officer with an explicit pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal read-through to biotech/therapeutics sector; this is company-specific insider transaction data.
No clear regional spillover expected from a single officer’s 10b5-1 sale.
Limited global relevance; not tied to clinical, regulatory, or financing events.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may ignore it.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; officer sale disclosed.
- insiderGoodman Noah
Chief Business Officer who sold shares under a pre-arranged 10b5-1 plan.
